INTRODUCTION

Fabry disease (FD, OMIM 301500) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism caused by a deficient or absent lysosomal αgalactosidase A (α-GLA) activity[1]. The prevalence of FD was once believed to be very rare, occurring approximately in 1:50000 patients[2]. Substrates of this lysosomal enzyme accumulate, resulting in cellular dysfunction in multiple organs. FD is commonly known as a silent disease that appears later in life and could be easily misdiagnosed. Patients lacking α-GLA activity exhibit a 10-20 year shortened life span:Male patients with FD have a median survival of 57 years, and the median female survival is 72 years[3].

Classically affected FD males with no residual α-GLA activity, may display neurological (pain and acroparesthesia), cutaneous (angiokeratoma), renal (proteinuria and kidney failure), cardiovascular (cardiomyopathy, arrhythmia, and valvulopathy),cochleovestibular, and cerebrovascular (transient ischemic attacks and strokes) signs while heterozygous females have symptoms ranging from mild to severe[1]. Male patients are usually severely affected, while the clinical presentation in female patients may be more variable[4].

There are currently 967 knownmutations, including 671 missense/nonsense mutations, listed in the Human Gene Mutation Database[5]. The type of amino acid exchange domain in the α-GLA 3D-structure determines the disease severity and temporal course of clinical presentation. Patients with active site or buried mutations showed a severe phenotype with multi-organ involvement and early disease manifestation. Patients with certain mutations showed a milder phenotype with less organ impairment and later disease onset[6]. In male patients, the α-GLA enzyme activity is often significantly decreased, while about a third of female patients have enzymes within the normal range.

Enzymatic measurement of α-GLA: The enzyme activity of α-GLA was reduced to only 1.0 nmol/h/mg protein in the son of the proband, while a normal range was observed in all other family members (Table 1).

In the present study, we describe a novel frameshift mutation inand different α-GLA enzymatic activity in a Chinese family in which both male and female members presented with left ventricular hypertrophy and atrial fibrillation.

CASE PRESENTATION

Chief complaints

After 6 mo of ERT, serum creatinine in the son of the proband had no significant decrease. The pain in his skin was markedly relieved.

正解：鋁能將NaOH中的+1價(jià)的H還原嗎?當(dāng)然不能,因?yàn)榧词故沁€原性極強(qiáng)的金屬鈉也不能和氫氧化鈉反應(yīng)放出氫氣,氫氧化鈉作氧化劑很顯然是錯(cuò)誤的。鋁和氫氧化鈉溶液反應(yīng)的實(shí)質(zhì)是:2Al+6H2O==2Al(OH)3↓+3H2↑,2Al(OH)3+2NaOH==2NaAlO2+4H2O。

History of present illness

A 57-year-old woman was diagnosed with left ventricular hypertrophy and atrial fibrillation 7 years ago. Echocardiography showed an end-diastolic diameter of the interventricular septum of 19.9 mm, left ventricular end-diastolic diameter of 63.1 mm,moderate-to-severe mitral regurgitation, and a left ventricular ejection fraction (LVEF)of 45%. Cardiac magnetic resonance (CMR) indicated an enlarged left heart and right atrium, decreased left ventricular systolic and diastolic function, an LVEF of about 20%, and thickening of the left ventricular septum. In March 2019, gene and enzyme activity tests confirmed the diagnosis of FD. Her son was diagnosed with FD after gene and enzyme activity assay, and was prescribed agalsidase-β for enzyme replacement therapy in July 2020. Two sisters of the proband were also diagnosed with FD by genetic testing. Both of them had a history of atrial fibrillation.

本研究立足于多模態(tài)理論和POA(Product-output Approach,產(chǎn)出導(dǎo)向教學(xué)法),針對(duì)目前高校英語(yǔ)聽(tīng)說(shuō)課教學(xué)存在的問(wèn)題,重點(diǎn)探討網(wǎng)絡(luò)多模態(tài)環(huán)境下POA對(duì)大學(xué)生多元聽(tīng)說(shuō)能力的培養(yǎng)。

History of past illness

The proband did not have any significant personal history. Her father died of cardiomyopathy, while her mother died of colon cancer. Her son and two sisters were diagnosed with FD.

Personal and family history

The proband had a history of hypertension for more than 20 years.

Physical examination

At the last admission, the proband’s blood pressure was 99/65 mmHg. She was conscious, but presented with an appearance of weakness. Her tongue stuck out to the right. Her jugular vein was filling. Rales could be heard widely over both lung fields.The heart rate was 96 bpm. The intensity of the first heart sound was unequal. Systolic murmur (III/6) was identified in the apex of the heart. There was no edema in her lower limbs.

Laboratory examinations

Enzyme replacement therapy (ERT) and chaperone therapy are currently considered the main targeted treatments for FD. As two representative drugs of enzyme replacement therapy, agalsidase-α and agalsidase-β have been shown to be clinically effective for patients with FD; yet, these are very expensive (approximately$200000 per patient annually in China). Some patients with amenablemutations have residual activity in α-GLA. In these patients, small molecular chaperones could promote enzyme stability and are clinically effective.

Clinical and biochemical studies: All of the patients in this family, whether hemizygous or heterozygote, had left ventricular hypertrophy. All female family members (II3, II5, and II7) had atrial fibrillation, except the propositus granddaughter(IV-1), who did not undergo inspection due to being only 2 years old. The levels of troponin I were all increased, and the ejection fraction was generally lower in female than male patients (III-2). Female heterozygotes suffered more severe cardiovascular damage while the kidney damage occurred earlier in males than in female family members. Stroke was more common in women, possibly due to atrial fibrillation and older age. At the same time, cutaneous and neuralgia manifestations were present in males of the same lineage, suggesting a wider range of glycosphingolipid deposition in the hemizygote and more involved organs (Table 1, Figure 1-5).

截至12月3日，全國(guó)共有21個(gè)省份發(fā)生79起家豬非洲豬瘟疫情，雖然疫情整體可控且并不傳人，但持續(xù)4月之后，非洲豬瘟對(duì)市場(chǎng)影響仍在不斷發(fā)酵。

The proband underwent atrial fibrillation radiofrequency ablation 7 years ago. Three years ago, she was given prednisone and tacrolimus because of edema and proteinuria. The son of the proband was given enzyme replacement therapy with agalsidase-β 65 mg (biweekly, intramuscularly) starting from July, 2020.

北京奇步自動(dòng)化控制設(shè)備有限公司是一家自動(dòng)化工程公司，以工業(yè)現(xiàn)場(chǎng)自動(dòng)化總線工程為發(fā)展方向，以“客戶創(chuàng)造價(jià)值”為宗旨，立志做自動(dòng)化領(lǐng)域一流企業(yè)。公司專業(yè)從事自動(dòng)化生產(chǎn)線系統(tǒng)集成、液壓（或氣動(dòng)）工裝夾具、物流線、自動(dòng)化精密元件、專業(yè)設(shè)備的技術(shù)研發(fā)、生產(chǎn)制造和銷售服務(wù)。公司嚴(yán)格執(zhí)行國(guó)際行業(yè)標(biāo)準(zhǔn)，認(rèn)真踐行ISO9001質(zhì)量體系標(biāo)準(zhǔn)和要求，以高質(zhì)量、標(biāo)準(zhǔn)化的產(chǎn)品以及完善的售后服務(wù)，贏得口碑，樹(shù)立品牌。

Imaging examinations

CMR showed patchy enhancement of interventricular septum and left ventricular anterior wall hypertrophy. Delayed enhancement suggested the formation of a large number of fibrous scars in left ventricular hypertrophy (Figure 3).

FINAL DIAGNOSIS

The final diagnosis of the presented case was FD.

TREATMENT

Gene expression: (1) Whole exome sequencing results: In this family, we found a frameshift mutation (348delG:p.G116fs) according to the guidelines for mutation nomenclature recommended by the Human Genome Variation Society (www.hgvs.org/mutnomen). The mutation occurred in the guanine deletion at position 348 of thegene, resulting in a series of changes in the code of the 116th amino acid and its downstream (Figure 6). This mutation causes a change in the GLA protein domain (Figure 7)[7,8]; and (2) Conventional sequencing results: Sanger sequencing confirmed that the mutation occurred due to the guanine deletion in exon 2. Figure 8A shows the gene sequencing results of the proband (II-3). Adenine takes the place of guanine, thus causing a rearrangement of the subsequent amino acid sequence. The son of the proband (III-2) and the two sisters showed the same mutation (Figure 8B and C).

OUTCOME AND FOLLOW-UP

The proband was a 57-year-old woman who has experienced paroxysmal chest tightness and shortness of breath for 7 years.

DISCUSSION

Thegene encoding α-Gal A is located on Xq22.1, with 7 exons and 12 kb in length[11]. Herein, we report a novel frameshift mutation in thegene in four members of a family with classical FD phenotype, with early-onset signs in affected men. Genotype-phenotype correlation in FD is challenging. Many GLA mutations are family-specific; in some families, there are quite marked phenotype variations. In contrast, the disease manifestation may vary within patients carrying the same mutation[12]. Garman[13] discovered two types of α-GLA mutations that are responsible for the disease progression: Mutations near the active sites and mutations of buried residues far from the active sites. Mutations near the active sites have a higher pathogenic frequency and severe clinical phenotype, while mutations far from the enzyme active sites are relatively mild[13]. The structure of α-GLA is a homodimeric glycoprotein with each monomer composed of two domains. The first domain contains the active site and extends from residues 32 to 330, and the second domain is comprised of residues 331-429, burying much surface area within one monomer. Rickert[6] found that patients with active site or buried mutations showed a severe phenotype with multi-organ involvement and early disease manifestation. Patients with other mutations had a milder phenotype with less organ impairment and later disease onset. In addition, the α-GalA activity was lower in patients with active site or buried mutations than in those with other mutations while lyso-Gb3 levels were higher.

8月18-20日，由國(guó)家糧食交易中心、中國(guó)貿(mào)促會(huì)糧食行業(yè)分會(huì)、黑龍江省糧食局承辦的首屆中國(guó)糧食交易大會(huì)在哈爾濱舉行，吸引了31個(gè)省、市、自治區(qū)政府代表團(tuán)成員和近千家糧食企業(yè)代表參會(huì)。國(guó)家糧食和物資儲(chǔ)備局局長(zhǎng)張務(wù)鋒表示，在糧食供需形勢(shì)發(fā)生深刻變化和糧食流通市場(chǎng)化水平不斷提高的背景下，首屆糧食交易大會(huì)是拓展產(chǎn)銷合作平臺(tái)、促進(jìn)糧食供需平衡的重大舉措，有利于增強(qiáng)中國(guó)糧食安全保障能力，有利于進(jìn)一步加強(qiáng)產(chǎn)銷合作，形成新的產(chǎn)銷格局。據(jù)國(guó)家糧食交易中心主任賈騫介紹，首屆中國(guó)糧食交易大會(huì)提供銷售糧源2240萬(wàn)噸，擬采購(gòu)各類糧油1970萬(wàn)噸，征集糧油產(chǎn)業(yè)經(jīng)濟(jì)投資洽談項(xiàng)目147個(gè)，涉及金額約520億元。

In the proband of our study, a frameshift mutation (348delG:p.G116fs) occurred due to the guanine deletion at position 348 of thegene, resulting in a series of changes in the code of the 116amino acid and its downstream, so that the GLA peptide chain was transformed into a completely different peptide sequence. Enzyme activity tests confirmed that the enzyme activity of the female members of the family was moderately decreased and that of the male members was extremely decreased.

The α-Gal activity in female subjects who carry a heterozygous pathogenic variant in thegene, is subject to X chromosome inactivation, typically random, celldependent, often nonuniform across the silenced chromosome[14]. Likewise, it complicates correlations among the genetic variants, functional data, and organ involvement. Nevertheless, as a group, α-Gal activity is higher in female subjects with pathogenic GLA variants than in male subjects' corresponding values. Consequently,up to one-third of X-chromosomal genes are expressed from both the active and inactive X chromosomes (Xa and Xi, respectively) in female cells, with the degree of“escape” from inactivation varying between genes and individuals[15], posing significant diagnostic challenges. In this study, the proband was a heterozygote but had classical characteristics such as heart failure and renal failure. Her sisters present nonclassical characteristics, whose manifestations are limited to cardiac involvement.

Clinically, FD diagnosis is primarily based on the clinical manifestation of multiple systems involving the brain, kidney, heart, and peripheral nerves, and also based on the comprehensive interrogation of family history. Patients may seek help from multiple medical specialists before a correct diagnosis is made, resulting in delayed treatment initiation[16]. Cardiac involvement is characterized by progressive cardiac hypertrophy, fibrosis, arrhythmias, heart failure, and sudden cardiac death. As myocardial fibrosis develops, the posterior and inferior LV wall can thin and become hypokinetic or akinetic[17]. Thinning of the LV posterior wall is a feature of FD related cardiomyopathy in the late stage. Further laboratory tests may include GLA activity test, pathological biopsy, and gene test, which are also considered the gold standard for diagnosis. Also, microscopic formation of typical onion-like osmiophilic inclusion bodies (such as myeloid corpuscle and zebra-corpuscle) in glomerular and tubular epithelial cell lysosomes is a typical pathological feature of lysosomal glycolipid aggregation, which is of great value in disease diagnosis. Early detection and treatment are crucial for achieving the best outcome.

Genetic testing, performed by whole-exome sequencing, and targeted analysis of thegene could confirm clinical diagnosis. Nevertheless, the findings of a missense variant should not be considered an unequivocal validation of the diagnosis. Recently,a study examined 115 Japanese families with FD. No pathogenic mutations were identified in six families (5.2%). In total, 73 different disease-causing mutations were identified: 41 missense (56.2%), 11 nonsense (15.1%), four in-frame deletion (5.5%), 10 frameshift (13.7%), six splice site (8.2%), and one intronic (1.4%)[18]. As a result, many GLA variants of unknown significance (VOS) were identified. Therefore, the diagnosis of FD should not over-rely on genetic testing, and both clinical manifestations and family history should be considered comprehensively[19].

The treatment of FD relies on specific and non-specific treatments. Non-specific treatment is used to deal with the involvement of various organs. In this family, all the women (II3, II5, and II7) developed atrial fibrillation and underwent radical ablation,and in one case (II5) left atrial appendage occlusion was performed. Specific treatments include ERT, which is currently approved to be marketed as a galactosidase-α and a galactosidase-β. In this study, the son of the proband had started ERT treatment, and the effect will be followed closely. The European Union also approved the molecular chaperone migalastat in 2016 for the long-term treatment of specific mutated FD in patients over the age of 16 years, which could increase endogenous α-Gal A activity in a prospective observational multicenter study[20]. Pretreatment clinical assessment, continuous clinical monitoring, and establishment and improvement of disease database should be made during treatment.

Since FD is an X-linked genetic disorder, genetic counseling and prenatal diagnosis should also be performed for all patients. Here we report a female patient who had a son who was also diagnosed with FD. The son had a daughter and he definitely passed the abnormal X chromosome to her (with 1 abnormal X chromosome and 1 normal X chromosome). However, the daughter has a heterozygousallele, which may have relatively mild clinical manifestations and still need to be followed closely.

實(shí)際使用中，不少機(jī)組將蜂窩汽封用于低壓缸末三級(jí)葉頂汽封，認(rèn)為借助其除濕功能可以減少葉片水蝕，這種做法是不科學(xué)的。核電廠汽輪機(jī)由于蒸汽參數(shù)低，葉片水蝕現(xiàn)象突出，汽輪機(jī)在制造時(shí)充分考慮到了蜂窩汽封除濕功能，在末幾級(jí)隔板安裝汽封的凹槽內(nèi)設(shè)有疏水孔。蜂窩部分與汽封塊母體采用分段間隔焊接的方式，留出了疏水通道，這些部位的蜂窩汽封起到除濕作用。但是，火電廠的汽輪機(jī)原設(shè)計(jì)使用的基本是梳齒汽封，沒(méi)有上述的相應(yīng)措施，滯留在“蜂窩”內(nèi)的積水無(wú)法排出，因此即便使用蜂窩汽封亦無(wú)法發(fā)揮它的除濕作用。

能源安全事關(guān)國(guó)家經(jīng)濟(jì)社會(huì)發(fā)展全局。建設(shè)堅(jiān)強(qiáng)智能電網(wǎng)，實(shí)現(xiàn)全球能源互聯(lián)既是我國(guó)電網(wǎng)發(fā)展建設(shè)的目標(biāo)，又是落實(shí)國(guó)家整體能源戰(zhàn)略的要點(diǎn)。在增加信息業(yè)務(wù)量和擴(kuò)大工作范圍的同時(shí)，智能電網(wǎng)建設(shè)的持續(xù)推進(jìn)勢(shì)必對(duì)電力通信系統(tǒng)的安全性、實(shí)時(shí)性和可靠性提出更高要求。保障通信光纜線路的聯(lián)絡(luò)順暢，防止梗塞和中斷出現(xiàn)，不但對(duì)于電力通信系統(tǒng)本身，而且對(duì)于整個(gè)電網(wǎng)系統(tǒng)均具有非常重要的現(xiàn)實(shí)意義。

CONCLUSION

In summary, our findings suggest that the novel mutation 348delG:p.G116fs may be associated with classical manifestations of FD. These new data can be helpful in the diagnosis of FD and increase clinical and molecular knowledge about the correlations between mutations in thegene, enzyme activity, and clinical phenotype of FD.

The authors would like to acknowledge the technical staff from the Berry Genomics for providing the genetic tests. We would also like to thank the Shanghai Jiaotong University School of Medicine, Shanghai Institute for Pediatric Research, and the Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province for their help with enzyme activity testing.